Business
Medicenna Announces Upcoming Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting
Medicenna Announces Upcoming Presentation at the American Society of Clinical Oncology (AS...
About this update from Medicenna Therapeutics Corp.
[{"type":"text","content":"\n\n\n\nMedicenna Announces Upcoming Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\n\nCanada NewsWire\nTORONTO and HOUSTON, May 16, 2019\n\n\n\nTORONTO and HOUSTON, May 16, 2019 /CNW/ - Medicenna Therapeutics Corp.  (\"Medicenna\" or \"the Company\") (TSX: MDNA, OTCQB: MDNAF), a clinical stage immuno-oncology company, today announced that Dr. Dina Randazzo of Duke University, will present updates related to the recently completed Phase 2b clinical trial of MDNA55 for the treatment of recurrent glioblastoma at the 2019 Annual Meeting of the American Society of Clinical Oncology (ASCO) to be held from May 31 to June 4, 2019 in Chicago, Illinois.\nThe details of the poster presentation are as follows:\nTitle: MDNA55: A Locally Administered IL4 Guided Toxin as a Targeted Treatment for Recurrent GlioblastomaSession Title: Central Nervous System TumorsPresenter: Dr. Dina Randazzo, DO, MS;  Assistant Professor of Neurosurgery, Duke University Medical CenterPoster #: 228  Abstract: #2039Date/Time: Sunday, June 2, 2019 from 8:00am to 11:00amLocation: Hall A, McCormick Place Convention Center, 2301 S King Dr, Chicago, IL 60616\nIn addition, Medicenna will have two abstracts published in the Conference Proceedings reporting (1) the use of multi-parametric MRI techniques to monitor tumor response in rGBM patients treated with MDNA55 in the recently completed Phase 2b clinical trial, and (2) preclinical data on its immuno-oncology pipeline candidate MDNA109.\nTitle: Multi-parametric MRI as supplement to mRANO criteria for response assessment to MDNA55 in Adults with Recurrent or Progressive Glioblastoma.First Author: Diana Roettger, PhDAbstract: #e13559\nTitle: MDNA109: An Interleukin-2 Superkine Exhibiting Improved CD8 T-cell Activating Properties in the Tumor Microenvironment.First Author: Moutih Rafei, PhDAbstract: #e14220\nAbstracts of the company's presentations are available at: abstracts.asco.org \nAbout Medicenna...